Sime Armoyan Sells 2,500,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 2,500,000 shares of the company’s stock in a transaction dated Friday, March 21st. The shares were sold at an average price of C$6.30, for a total transaction of C$15,750,000.00.

Sime Armoyan also recently made the following trade(s):

• On Wednesday, March 19th, Sime Armoyan sold 550,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.20, for a total value of C$3,410,000.00.
• On Monday, March 17th, Sime Armoyan sold 92,200 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.15, for a total value of C$567,030.00.
• On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.10, for a total value of C$6,710.00.
• On Tuesday, March 4th, Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock. The shares were purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Stock Up 0.5 %

GUD stock opened at C$6.04 on Thursday. The stock has a market cap of C$610.95 million, a PE ratio of -20.16, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The firm’s 50-day simple moving average is C$5.72 and its 200 day simple moving average is C$5.59. Knight Therapeutics Inc. has a fifty-two week low of C$5.09 and a fifty-two week high of C$6.45. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52.

Analyst Ratings Changes

A number of brokerages have weighed in on GUD. Stifel Nicolaus increased their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a “buy” rating in a report on Tuesday. Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group cut Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Knight Therapeutics presently has a consensus rating of “Buy” and a consensus price target of C$7.48.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.